University of Louisville, Medical Dental Complex
Welcome,         Profile    Billing    Logout  
 0 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cave, Matthew
NCT05239468 / 2022-001241-20: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Active, not recruiting
2
60
US
Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo
Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.
Primary Biliary Cholangitis
11/24
02/25
Siegwald, Angela
PATENT-E, NCT05561114: Paclitaxel Coated Balloon for the Treatment of Chronic BEnigN STricture- Esophagus

Recruiting
3
198
US
GIE Medical ProTractX3 TTS DCB, Control
GIE Medical
Esophageal Stricture
07/25
12/29
PATENT-B, NCT05561127: Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel

Recruiting
3
171
US
GIE Medical ProTractX3 TTS DCB, Control
GIE Medical
Bowel; Stricture
09/26
03/29
NCI-2018-00047, NCT03456843: Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

Recruiting
2
190
Japan, US, RoW
Antiandrogen Therapy, ADT, Androgen Deprivation Therapy, Anti-androgen Therapy, Anti-androgen Treatment, Antiandrogen Treatment, Hormone Deprivation Therapy, Hormone-Deprivation Therapy, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radical Prostatectomy, Prostatovesiculectomy
Yale University, National Cancer Institute (NCI)
Stage IV Prostate Adenocarcinoma AJCC v7
03/27
03/27
NCT05437029: Safety, Tolerability, and Pharmacokinetics of Q-Griffithsin Intranasal Spray

Recruiting
1b
24
US
Q-Griffithsin 3.0, Q-Griffithsin Group 1, Q-Griffithsin 6.0, Q-Griffithsin Group 2
Kenneth Palmer, United States Department of Defense
COVID-19 Prevention
10/22
11/22
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Suspended
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
NCT02815891: A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

Recruiting
N/A
15000
Europe, US
Target PharmaSolutions, Inc.
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
07/36
07/36

Download Options